当前位置: X-MOL 学术ChemMedChem › 论文详情
Our official English website, www.x-mol.net, welcomes your feedback! (Note: you will need to create a separate account there.)
Structure-Based Design, Synthesis, and Biological Evaluation of Triazole-Based smHDAC8 Inhibitors.
ChemMedChem ( IF 3.4 ) Pub Date : 2020-01-09 , DOI: 10.1002/cmdc.201900583
Dmitrii V Kalinin 1, 2, 3, 4 , Sunit K Jana 3, 5 , Maxim Pfafenrot 3 , Alokta Chakrabarti 6 , Jelena Melesina 7 , Tajith B Shaik 8 , Julien Lancelot 9 , Raymond J Pierce 9 , Wolfgang Sippl 7 , Christophe Romier 8 , Manfred Jung 6 , Ralph Holl 1, 2
Affiliation  

Schistosomiasis is a neglected tropical disease caused by parasitic flatworms of the genus Schistosoma, which affects over 200 million people worldwide and leads to at least 300,000 deaths every year. In this study, initial screening revealed the triazole-based hydroxamate 2 b (N-hydroxy-1-phenyl-1H-1,2,3-triazole-4-carboxamide) exhibiting potent inhibitory activity toward the novel antiparasitic target Schistosoma mansoni histone deacetylase 8 (smHDAC8) and promising selectivity over the major human HDACs. Subsequent crystallographic studies of the 2 b/smHDAC8 complex revealed key interactions between the inhibitor and the enzyme's active site, thus explaining the unique selectivity profile of the inhibitor. Further chemical modifications of 2 b led to the discovery of 4-fluorophenoxy derivative 21 (1-[5-chloro-2-(4-fluorophenoxy)phenyl]-N-hydroxy-1H-1,2,3-triazole-4-carboxamide), a nanomolar smHDAC8 inhibitor (IC50 =0.5 μM), exceeding the smHDAC8 inhibitory activity of 2 b and SAHA (vorinostat), while exhibiting an improved selectivity profile over the investigated human HDACs. Collectively, this study reveals specific interactions between smHDAC8 and the synthesized triazole-based inhibitors and demonstrates that these small molecules represent promising lead structures, which could be further developed in the search for novel drugs for the treatment of schistosomiasis.

中文翻译:

基于三唑的smHDAC8抑制剂的基于结构的设计,合成和生物学评估。

血吸虫病是由血吸虫属的寄生性扁虫引起的一种被忽视的热带病,它影响全世界2亿多人,每年导致至少30万人死亡。在这项研究中,初步筛选显示基于三唑的异羟肟酸酯2 b(N-羟基-1-苯基-1H-1,2,3-三唑-4-羧酰胺)对新型抗寄生虫靶曼氏血吸虫组蛋白脱乙酰基酶表现出有效的抑制活性8(smHDAC8)和对主要人类HDAC的有希望的选择性。随后的2 b / smHDAC8复合物的晶体学研究显示抑制剂与酶的活性位点之间的关键相互作用,从而解释了抑制剂的独特选择性。2 b的进一步化学修饰导致发现4-氟苯氧基衍生物21(1- [5-氯-2-(4-氟苯氧基)苯基] -N-羟基-1H-1,2,3-三唑-4-羧酰胺),一种纳摩尔浓度的smHDAC8抑制剂(IC50 = 0.5μM),超过了2b和SAHA(伏立诺他)的smHDAC8抑制活性,同时表现出比所研究的人类HDAC更高的选择性。总的来说,这项研究揭示了smHDAC8与合成的基于三唑的抑制剂之间的特异性相互作用,并表明这些小分子代表了有前途的铅结构,可以在寻找用于治疗血吸虫病的新药中进一步发展。同时表现出比所研究的人类HDAC更高的选择性。总的来说,这项研究揭示了smHDAC8与合成的基于三唑的抑制剂之间的特异性相互作用,并表明这些小分子代表了有前途的铅结构,可以在寻找用于治疗血吸虫病的新药中进一步发展。同时表现出比所研究的人类HDAC更高的选择性。总的来说,这项研究揭示了smHDAC8与合成的基于三唑的抑制剂之间的特异性相互作用,并表明这些小分子代表了有前途的铅结构,可以在寻找用于治疗血吸虫病的新药中进一步发展。
更新日期:2020-01-09
down
wechat
bug